Cynata Therapeutics Management
Management criteria checks 3/4
Cynata Therapeutics' CEO is Kilian Kelly, appointed in Jul 2023, has a tenure of 1.33 years. total yearly compensation is A$544.83K, comprised of 71.7% salary and 28.3% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$133.22K. The average tenure of the management team and the board of directors is 2.2 years and 4.4 years respectively.
Key information
Kilian Kelly
Chief executive officer
AU$544.8k
Total compensation
| CEO salary percentage | 71.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$545k | AU$391k | -AU$10m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$14m |
| Sep 30 2023 | n/a | n/a | -AU$14m |
| Jun 30 2023 | AU$413k | AU$334k | -AU$14m |
| Mar 31 2023 | n/a | n/a | -AU$12m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$7m |
| Jun 30 2022 | AU$499k | AU$313k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$4m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$737k | AU$300k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$7m |
| Dec 31 2020 | n/a | n/a | -AU$6m |
| Sep 30 2020 | n/a | n/a | -AU$5m |
| Jun 30 2020 | AU$472k | AU$300k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$6m |
| Dec 31 2019 | n/a | n/a | -AU$8m |
| Sep 30 2019 | n/a | n/a | -AU$8m |
| Jun 30 2019 | AU$449k | AU$279k | -AU$8m |
| Mar 31 2019 | n/a | n/a | -AU$7m |
| Dec 31 2018 | n/a | n/a | -AU$6m |
| Sep 30 2018 | n/a | n/a | -AU$5m |
| Jun 30 2018 | AU$357k | AU$259k | -AU$5m |
Compensation vs Market: Kilian's total compensation ($USD354.06K) is about average for companies of similar size in the Australian market ($USD297.81K).
Compensation vs Earnings: Kilian's compensation has increased whilst the company is unprofitable.
CEO
Kilian Kelly
1.3yrs
Tenure
AU$544,827
Compensation
Dr. Kilian Kelly has been Chief Executive Officer and Managing Director at Cynata Therapeutics Limited since July 1, 2023 and has been its Director since 2023 and had been its Chief Operating Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.3yrs | AU$544.83k | 0.34% A$ 133.2k | |
| Chief Medical Officer | 3.1yrs | AU$398.72k | no data | |
| Chief Business Officer | less than a year | AU$379.02k | no data | |
| Company Secretary | 12.6yrs | AU$140.00k | no data |
2.2yrs
Average Tenure
Experienced Management: CYP's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.8yrs | AU$544.83k | 0.34% A$ 133.2k | |
| Independent Non-Executive Chairman | 5.5yrs | AU$138.77k | 0.14% A$ 55.3k | |
| Independent Non-Executive Director | 8.4yrs | AU$68.20k | 0.17% A$ 67.8k | |
| Independent Non-Executive Director | 2.2yrs | AU$81.69k | 0.064% A$ 25.0k | |
| Independent Non-Executive Director | 4.4yrs | AU$68.20k | 0.028% A$ 10.7k |
4.4yrs
Average Tenure
64yo
Average Age
Experienced Board: CYP's board of directors are considered experienced (4.4 years average tenure).